Skip to content

Study · Randomized controlled trial · n = 8 · 1997

7 results

Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans.

Lamrani A, Vidon N, Sogni P, Nepveux P, Catus F, Blumberg J, Chaussade S

British journal of clinical pharmacology1 Jan 1997Cited by 12 (Europe PMC)

PMID9056054 (opens in a new tab)DOI10.1111/j.1365-2125.1997.tb00034.x (opens in a new tab)PepBankPUB-09056054
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy men, lanreotide significantly decreased gastric acid secretion by 90% during the initial 3 h compared with placebo.

    In plain wordsIn healthy men, lanreotide reduced stomach acid secretion by 90% during the initial 3 h compared with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseGastric acid secretion
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    100 micrograms h-t after a bolus of 100 micrograms · intravenousAs given in this study (human).

    Measurements

    Gastric acid secretion decrease
    90%
    initial 3 h versus placebo

    Source sentences

    Summary
    Lanreotide significantly decreased gastric acid secretion (90%) for the initial 3 h period.
    2 context sentences
    Summary · context
    Eight healthy male volunteers were studied on two occasions within a 2 weeks interval, using a perfusion method.
    Summary · context
    They received in single-blind and random order continuous i.v. infusion of either placebo or lanreotide (100 micrograms h-t after a bolus of 100 micrograms 15 min before the beginning of the study).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy men, lanreotide did not significantly modify gastric emptying compared with placebo.

    In plain wordsIn healthy men, lanreotide did not significantly change stomach emptying compared with placebo.

    Peptide
    Lanreotide
    Outcome
    No significant changeGastric emptying
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    100 micrograms h-t after a bolus of 100 micrograms · intravenousAs given in this study (human).

    Source sentences

    Summary
    Gastric emptying was not significantly modified by lanreotide infusion.
    2 context sentences
    Summary · context
    Eight healthy male volunteers were studied on two occasions within a 2 weeks interval, using a perfusion method.
    Summary · context
    They received in single-blind and random order continuous i.v. infusion of either placebo or lanreotide (100 micrograms h-t after a bolus of 100 micrograms 15 min before the beginning of the study).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy men, lanreotide almost completely abolished the bile salt response to a meal compared with placebo.

    In plain wordsIn healthy men, lanreotide almost completely blocked the bile salt response to a meal compared with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseMeal-induced bile salt response
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    100 micrograms h-t after a bolus of 100 micrograms · intravenousAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, lanreotide almost completely abolished both bile salts and lipase responses to the meal.
    2 context sentences
    Summary · context
    Eight healthy male volunteers were studied on two occasions within a 2 weeks interval, using a perfusion method.
    Summary · context
    They received in single-blind and random order continuous i.v. infusion of either placebo or lanreotide (100 micrograms h-t after a bolus of 100 micrograms 15 min before the beginning of the study).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy men, lanreotide almost completely abolished the lipase response to a meal compared with placebo.

    In plain wordsIn healthy men, lanreotide almost completely blocked the lipase response to a meal compared with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseMeal-induced lipase response
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    100 micrograms h-t after a bolus of 100 micrograms · intravenousAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, lanreotide almost completely abolished both bile salts and lipase responses to the meal.
    2 context sentences
    Summary · context
    Eight healthy male volunteers were studied on two occasions within a 2 weeks interval, using a perfusion method.
    Summary · context
    They received in single-blind and random order continuous i.v. infusion of either placebo or lanreotide (100 micrograms h-t after a bolus of 100 micrograms 15 min before the beginning of the study).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy men, lanreotide largely increased duodeno-caecal transit time compared with placebo.

    In plain wordsIn healthy men, lanreotide increased intestinal transit time compared with placebo.

    Peptide
    Lanreotide
    Outcome
    IncreaseDuodeno-caecal transit time
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    100 micrograms h-t after a bolus of 100 micrograms · intravenousAs given in this study (human).

    Source sentences

    Summary
    It largely increased the duodeno-caecal transit time and decreased significantly the duodenal absorption of carbohydrates and triglycerides.
    2 context sentences
    Summary · context
    Eight healthy male volunteers were studied on two occasions within a 2 weeks interval, using a perfusion method.
    Summary · context
    They received in single-blind and random order continuous i.v. infusion of either placebo or lanreotide (100 micrograms h-t after a bolus of 100 micrograms 15 min before the beginning of the study).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In healthy men, lanreotide significantly decreased duodenal carbohydrate absorption compared with placebo.

    In plain wordsIn healthy men, lanreotide reduced carbohydrate absorption in the duodenum compared with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseDuodenal carbohydrate absorption
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    100 micrograms h-t after a bolus of 100 micrograms · intravenousAs given in this study (human).

    Source sentences

    Summary
    It largely increased the duodeno-caecal transit time and decreased significantly the duodenal absorption of carbohydrates and triglycerides.
    2 context sentences
    Summary · context
    Eight healthy male volunteers were studied on two occasions within a 2 weeks interval, using a perfusion method.
    Summary · context
    They received in single-blind and random order continuous i.v. infusion of either placebo or lanreotide (100 micrograms h-t after a bolus of 100 micrograms 15 min before the beginning of the study).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In healthy men, lanreotide significantly decreased duodenal triglyceride absorption compared with placebo.

    In plain wordsIn healthy men, lanreotide reduced triglyceride absorption in the duodenum compared with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseDuodenal triglyceride absorption
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    100 micrograms h-t after a bolus of 100 micrograms · intravenousAs given in this study (human).

    Source sentences

    Summary
    It largely increased the duodeno-caecal transit time and decreased significantly the duodenal absorption of carbohydrates and triglycerides.
    2 context sentences
    Summary · context
    Eight healthy male volunteers were studied on two occasions within a 2 weeks interval, using a perfusion method.
    Summary · context
    They received in single-blind and random order continuous i.v. infusion of either placebo or lanreotide (100 micrograms h-t after a bolus of 100 micrograms 15 min before the beginning of the study).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT03012594

Lanreotide in the Treatment of Small Bowel Motility Disorders

Northwell Healthn = 1211 May 2017 to 11 Mar 2019

Gastrointestinal Motility Disorder · Intestinal Disease

Trial pageClinicalTrials.govUpdated 15 Jan 2021
Status unknownPhase 2NCT02054637

Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy

Universitair Ziekenhuis Brusseln = 10Apr 2014 to est. Apr 2016

Acid Reflux Esophagitis · Non-acid Reflux Esophagitis

Trial pageClinicalTrials.govUpdated 4 Feb 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.